Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension
Oxlund, C S, Cangemi, C, Henriksen, J E, Jacobsen, I A, Gram, J, Schousboe, K, Tarnow, L, Argraves, W S, Rasmussen, L M
Published in Journal of human hypertension (01.01.2015)
Published in Journal of human hypertension (01.01.2015)
Get full text
Journal Article
419Body mass index and intensive blood pressure management in high-risk adults: insights from the systolic blood pressure intervention trial SPRINT
Pareek, M, Vaduganathan, M, Biering-Sorensen, T, Oxlund, C S, Rasmussen, B S, Olsen, M H, Bhatt, D L
Published in European heart journal (01.08.2018)
Published in European heart journal (01.08.2018)
Get full text
Journal Article
The mineralocorticoid receptor blocker spironolactone lowers plasma interferon-γ and interleukin-6 in patients with type 2 diabetes and treatment-resistant hypertension
Thangaraj, Sai Sindhu, Oxlund, Christina Stolzenburg, Fonseca, Micaella Pereira Da, Svenningsen, Per, Stubbe, Jane, Palarasah, Yaseelan, Ketelhuth, Daniel F J, Jacobsen, Ib Abildgaard, Jensen, Boye L
Published in Journal of hypertension (01.01.2022)
Published in Journal of hypertension (01.01.2022)
Get more information
Journal Article